Administration of Misoprostol versus Hyoscine Butylbromide Prior to Hysteroscopy as a Cervical Priming Agent
Elsayed, M., Abd Elfatah, A., Mohamed, A., Elsayed, H. (2023). Administration of Misoprostol versus Hyoscine Butylbromide Prior to Hysteroscopy as a Cervical Priming Agent. EKB Journal Management System, 92(1), 5640-5646. doi: 10.21608/ejhm.2023.306895
Marwa Ahmed Elsayed; Ashraf Talat Abd Elfatah; Ahmed Ismail Mohamed; Hala Sherif Elsayed. "Administration of Misoprostol versus Hyoscine Butylbromide Prior to Hysteroscopy as a Cervical Priming Agent". EKB Journal Management System, 92, 1, 2023, 5640-5646. doi: 10.21608/ejhm.2023.306895
Elsayed, M., Abd Elfatah, A., Mohamed, A., Elsayed, H. (2023). 'Administration of Misoprostol versus Hyoscine Butylbromide Prior to Hysteroscopy as a Cervical Priming Agent', EKB Journal Management System, 92(1), pp. 5640-5646. doi: 10.21608/ejhm.2023.306895
Elsayed, M., Abd Elfatah, A., Mohamed, A., Elsayed, H. Administration of Misoprostol versus Hyoscine Butylbromide Prior to Hysteroscopy as a Cervical Priming Agent. EKB Journal Management System, 2023; 92(1): 5640-5646. doi: 10.21608/ejhm.2023.306895

Administration of Misoprostol versus Hyoscine Butylbromide Prior to Hysteroscopy as a Cervical Priming Agent

The Egyptian Journal of Hospital Medicine
Article 27, Volume 92, Issue 1, July 2023, Page 5640-5646  XML PDF (670.5 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2023.306895
View on SCiNiTO View on SCiNiTO
Authors
Marwa Ahmed Elsayed email ; Ashraf Talat Abd Elfatah; Ahmed Ismail Mohamed; Hala Sherif Elsayed
Abstract
 
 
 
Background: A treatment called hysteroscopy is used to examine and treat a number of gynecological issues.
Objective: To compare misoprostol versus hyoscine butylbromide as a cervical priming agent in patients underlying hysteroscopy.
Patients and methods: This randomized controlled clinical trial was carried out on 82 participants who were scheduled for operative hysteroscopy at Obstetrics and Gynecology Department, Zagazig University Hospitals. All participants in our study were divided randomly for cervical ripening prior to hysteroscopy into two groups; Group (A): Misoprostol was administrated (n=41), Group (B): Hyoscine butylbromide was administrated (n= 41). All patients were subjected to full history taking, routine clinical examination and laboratory investigations. The cervical priming agent was administrated 2 hours before the scheduled hysteroscopy.
Results: There was no statistically significant difference between the two studied groups regarding age, height, weight, BMI, the mean parity, previous history of CS, history of abortion, the diagnosis, the procedure time, and anesthesia. Cervical dilatation width was significantly higher among group A while cervical dilatation time was significantly lower among group A than group B. The self-reported pain was significantly higher among group A than group B. Nearly 44% of the participants of group A needed postoperative analgesia administration, while only 12.2% of group B needed postoperative analgesia administration.
Conclusion: Hyoscine butylbromide is as effective as misoprostol as a cervical priming agent in patients undergoing operative hysteroscopy with less need for postoperative pain medication and postoperative complications.
 
Keywords
Hysteroscopy; Misoprostol; Hyoscine Butylbromide; Cervical Priming Agent
Statistics
Article View: 146
PDF Download: 243